SAN DIEGO, Oct. 30 /CNW/ -- Nventa Biopharmaceuticals Corporation (TSX:
NVN) announced today that Gregory M. McKee, the Company's President and Chief
Executive Officer, is scheduled to make a presentation on Thursday, November
1, 2007 at 10:30 am Pacific Time at the BIOCOM Investor Conference 2007, which
is taking place at the San Diego Marriott Del Mar Hotel.
Gregory McKee will provide an overview of the Company and will discuss
the Company's progress with its investigational therapeutic vaccine, HspE7 for
human papillomavirus (HPV)-related diseases, and also the Company's business
strategy. An audio webcast of Nventa's presentation, with an accompanying
slide presentation, will be available on
http://events.powerstream.net/002/00436/20071101_SDIC/ or on the Company's
website at http://www.nventacorp.com on the day of the event. Participants
will need to allow adequate time to download any software necessary for the
About Nventa Biopharmaceuticals Corporation:
Nventa is developing innovative therapeutics for the treatment of viral
infections and cancer, with a focus on diseases caused by the human
papillomavirus (HPV). The corporation is publicly traded on the Toronto Stock
Exchange under the symbol NVN.
For more information about Nventa Biopharmaceuticals Corporation, please
visit the Company's website located at http://www.nventacorp.com.
For further information:
For further information: Donna Slade, Director, Investor Relations of
Nventa Biopharmaceuticals Corporation, +1-858-202-4945, fax, +1-858-450-6849,
firstname.lastname@example.org Web Site: http://www.nventacorp.com